TY - JOUR
T1 - Pioglitazone, nuclear receptors, and aerodigestive prevention
AU - Ondrey, Frank G.
N1 - Publisher Copyright:
©2019 American Association for Cancer Research.
PY - 2019
Y1 - 2019
N2 - There has been intense interest in nuclear receptor targeting for cancer prevention. With the exception of estrogen antagonism in breast carcinoma there has not been widespread adoption or success of this strategy in clinical cancer prevention. Keith and colleagues have performed a careful study, which utilized the PPARγ nuclear receptor agonist, pioglitazone, a common type II diabetes agent, in subjects at risk for lung carcinoma. Although the results are not promising with this strategy, the study provides evidence for feasibility accrual and biomarker strategies that could be utilized to gain additional insight in future trials.
AB - There has been intense interest in nuclear receptor targeting for cancer prevention. With the exception of estrogen antagonism in breast carcinoma there has not been widespread adoption or success of this strategy in clinical cancer prevention. Keith and colleagues have performed a careful study, which utilized the PPARγ nuclear receptor agonist, pioglitazone, a common type II diabetes agent, in subjects at risk for lung carcinoma. Although the results are not promising with this strategy, the study provides evidence for feasibility accrual and biomarker strategies that could be utilized to gain additional insight in future trials.
UR - http://www.scopus.com/inward/record.url?scp=85072849133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072849133&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-19-0341
DO - 10.1158/1940-6207.CAPR-19-0341
M3 - Review article
C2 - 31537582
AN - SCOPUS:85072849133
SN - 1940-6207
VL - 12
SP - 641
EP - 643
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 10
ER -